Sangamo Therapeutics (SGMO) SVP and CTO Michael Holmes to Resign

Go back to Sangamo Therapeutics (SGMO) SVP and CTO Michael Holmes to Resign

Sangamo Therapeutics Announces Technology Leadership Changes

July 13, 2018 4:15 PM EDT

RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately.

... More